Pharmacokinetics of anakinra in subjects with different levels of renal function

Publisher Website
Google Scholar
Abstract
Objective Our objective was to assess the effects of decreased renal function and dialysis on anakinra pharmacokinetics. Methods In 2 separate studies anakinra (1 mg/kg) was given intravenously to 12 healthy subjects and 20 subjects with end‐stage renal disease undergoing dialysis. In a third study anakinra (100 mg) was given subcutaneously to 30 subjects who had been assigned to 5 groups according to renal function, as follows: normal (creatinine clearance [CLcr] >80 mL/min), mildly impaired (CLcr = 50‐80 mL/min), moderately impaired (CLcr = 30‐49 mL/min), severely impaired (CLcr P < .0001). The removal of anakinra by dialysis was less than 2.5% of the dose administered. Compared with mean anakinra clearance (CL/F) after subcutaneous administration in the group with normal renal function (170 ± 37 mL/min), CL/F was reduced by 16% in the mildly impaired group (142 ± 59 mL/min), by 50% in the moderately impaired group (84.5 ± 24.7 mL/min, P < .05), by 70% in the severely impaired group (51.5 ± 8.4 mL/min, P < .05), and by 75% in the group with end‐stage renal disease (42.7 ± 4.7 mL/min, P < .05). A significant correlation between anakinra CL/F and CLcr was observed [log(CL/F) = 1.65 + 0.0062 · CLcr; r2 = 0.718]. Conclusion Anakinra is predominantly cleared renally in humans; the plasma clearance of anakinra decreased with decreasing renal function. The dialysis process has a minimal effect on the removal of anakinra. Our results suggest that a dose or schedule adjustment is indicated for persons with severe renal impairment or end‐stage renal disease. Clinical Pharmacology & Therapeutics (2003) 74, 85–94; doi: 10.1016/S0009‐9236(03)00094‐8

This publication has 0 references indexed in Scilit: